Related Experiment Video
Updated: Mar 15, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
[Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized,
P Denis1,
1Hospices civils de Lyon, service d'ophtalmologie, hôpital de la Croix-Rousse, 103, boulevard de la Croix-Rousse, 69317 Lyon cedex 04, France.
Objectives:
To evaluate the safety and efficacy of unpreserved latanoprost eye drops (UNL) in comparison with preserved latanoprost eye drops (LBAK) in patients with glaucoma or ocular hypertension stabilized with preserved latanoprost eye drops as monotherapy.
Methods:
Multicenter, randomized, open, two-parallel group study. The intraocular pressure (IOP), ocular signs and symptoms, adverse events and a quality of life questionnaire were evaluated at inclusion (D0) and after 3 months of treatment (D84).
Results:
One hundred and eighty-three patients were evaluated (38.7 % with an ocular hypertension and 61.3 % with open-angle glaucoma): 130 in the UNL group and 53 in the LBAK group). In the UNL group, mean IOP remained unchanged after 3 months of treatment and the mean difference with LBAK was 0.503mmHg with a confidence interval between -0.202 and 1.208, establishing non-inferiority of UN-L versus BAK-L. Overall, the total score of conjunctival hyperemia improved to a greater extent in the UNL group (-0.5±0.8) compared to the LBAK group (-0.1±0.6, P=0.0004), as well as the total score of symptoms on instillation (-2.0±2.7 versus -0.9±2.2, P=0.0035), and between instillations (-1.8±2.8 vs. -0.3±1.3, P=0.0003).
Conclusion:
The results of this study showed that preserved latanoprost eye drops may be substituted with unpreserved latanoprost eye drops with better tolerability in glaucoma patients with stable IOP.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Ophthalmic Drug Delivery Systems
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

